Nerve growth factor serum concentrations rise after successful cognitive–behavioural therapy of generalized anxiety disorder

Jockers-Scherübl, Maria C.; Zubraegel, Doris; Baer, Thomas M.; Danker‐Hopfe, Heidi; Schulte‐Herbrüggen, Olaf; Neu, Peter; Hellweg, Rainer

doi:10.1016/j.pnpbp.2006.09.006

Cited by 32 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A rise in serum NGF is also an indicator of positive treatment response in generalised anxiety disorder patients following CBT. 30 One possibility is that children with the T allele may show subtle differences in neurotrophic signalling that influence the extent to which environmental influences bring about neuroplastic modifications, which in turn modulate the mood.…”

Section: Discussionmentioning

confidence: 99%

“…28, 29 NGF serum levels also rise in response to positive environments, namely, after successful but not unsuccessful CBT treatment for generalised anxiety disorder. 30 Allelic variations at the rs6330 locus have previously shown associations with anxiety-related traits and affective disorders. NGF genotype interacted with gender to predict trait-anxiety scores, with higher anxiety seen in females with the CC genotype compared with CT and TT genotype carriers, but with the opposite effect observed in males.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neurotrophic gene polymorphisms and response to psychological therapy

et al. 2012

View full text Add to dashboard Cite

Therapygenetics, the study of genetic determinants of response to psychological therapies, is in its infancy. Here, we investigate whether single-nucleotide polymorphisms in nerve growth factor (NGF) (rs6330) and brain-derived neutrotrophic factor (BDNF) (rs6265) genes predict the response to cognitive behaviour therapy (CBT). Neurotrophic genes represent plausible candidate genes: they are implicated in synaptic plasticity, response to stress, and are widely expressed in brain areas involved in mood and cognition. Allelic variation at both loci has shown associations with anxiety-related phenotypes. A sample of 374 anxiety-disordered children with white European ancestry was recruited from clinics in Reading, UK, and in Sydney, Australia. Participants received manualised CBT treatment and DNA was collected from buccal cells using cheek swabs. Treatment response was assessed at post-treatment and follow-up time points. We report first evidence that children with one or more copies of the T allele of NGF rs6330 were significantly more likely to be free of their primary anxiety diagnosis at follow-up (OR=0.60 (0.42–0.85), P=0.005). These effects remained even when other clinically relevant covariates were accounted for (OR=0.62 (0.41–0.92), P=0.019). No significant associations were observed between BDNF rs6265 and response to psychological therapy. These findings demonstrate that knowledge of genetic markers has the potential to inform clinical treatment decisions for psychotherapeutic interventions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Neurotrophic gene polymorphisms and response to psychological therapy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…GAD patients presented an increase in NGF levels compared to non-GAD patients. A previous study by Jockers-Scherübl et al42 did not observe differences between GAD patients and healthy subjects. However, our sample have no control group to compare with mental disorders.…”

Section: Discussionmentioning

confidence: 74%

Mental disorders, functional impairment, and nerve growth factor

Salles¹,

Soares²,

Wiener³

et al. 2016

PRBM

View full text Add to dashboard Cite

Nerve growth factor (NGF) is an important member of the neurotrophin family and its alteration has been associated with psychiatric disorders. Functionality consists of the activities that an individual can perform, as well as their social participation, which is an important factor in analyzing the carrier living conditions of subjects with psychiatric suffering. Several studies have evaluated functionality in bipolar disorder; however, no studies have evaluated the functionality in other mental disorders. There are also few studies investigating the association between functionality and the biological bases of mental disorders. This study aimed to evaluate the serum NGF levels in psychiatric patients and to verify a possible association between the serum neurotrophic levels and functionality. This was a cross-sectional study with a convenient sample obtained from the Public Mental Health Service from the south of Brazil. The final sample was composed of 286 patients enrolled from July 2013 to October 2014. Data was collected using a sociodemographic questionnaire, and the diagnosis was confirmed using the Mini International Neuropsychiatric Interview (M.I.N.I) and a Functioning Assessment Short Test. The serum NGF levels were determined using the enzyme-linked immunosorbent assay method. Statistical analyses were performed using IBM SPSS Statistic 21.0 software. NGF serum levels were increased significantly in patients with obsessive–compulsive disorder compared with patients with no obsessive–compulsive disorder (P=0.015). An increase in serum NGF levels in generalized anxiety disorder patients was observed compared with patients with no generalized anxiety disorder (P=0.047). NGF was negatively associated with autonomy (P=0.024, r=−0.136), work (P=0.040, r=−0.124), and cognition (P=0.024, r=−0.137), thereby showing that changes in serum levels of NGF are associated with functionality in mental disorders.

show abstract

“…The mature form of nerve growth factor derives from a precursor, which was recently discovered to exert crucial brain functions responsible for mood and cognitive activities [59]. It was reported that in generalized anxiety disorder the blood levels of nerve growth factor increase after successful cognitive behavioral therapy [60]. Moreover, decreased blood levels of this protein in patients with SCZ were observed [61,62].…”

Section: Resultsmentioning

confidence: 99%

Genetic Variations Associated with Brain Disorders: Focus on Synaptic Plasticity and Apoptosis Regulatory Genes in Schizophrenia, Posttraumatic Stress Disorder and Ischemic Stroke

Boyajyan¹

2014

IJGG

View full text Add to dashboard Cite

Abstract:Epidemiologic, clinical and experimental data indicates that a majority of brain disorders including schizophrenia (SCZ), posttraumatic stress disorder (PTSD), and ischemic stroke (IS) are multifactorial disorders with strong and complex genetic component. Identification of all genetic variations associated with these disorders may sufficiently contribute to understanding of their basic pathomechanisms and encourage development of new innovative approaches to their early diagnosis and treatment. The aim of this review article is to provide overview of our recent studies on evaluation of potential association of SCZ, PTSD and IS with functional single nucleotide polymorphisms (SNPs) of synaptic plasticity and apoptosis regulatory genes in Armenian population. Here, our attention was focused on genes encoding netrin G1 (NTNG1), brain-derived neurotrophic factor (BDNF), complexin-2 (CPLX2), nerve growth factor (NGF) and its receptor (NGFR), annexin family proteins -annexin A5 and annexin A11 (ANXAV, ANXA11), and B-cell lymphoma 2 (Bcl-2) family proteins -Bcl-2 proper and Bcl-2-associated X protein (BCL2, BAX). Genomic DNA samples of diseased and healthy individuals were genotyped for a number of SNPs of the mentioned genes using polymerase chain reaction with sequence-specific primers (PCR-SSP). The significance of differences in genotype and allele frequencies and minor allele carriage between patients and healthy control subjects was determined using Pearson's Chi-square test. P-values less than 0.05 were considered statistically significant. Significant associations were found between: (1) SCZ and BDNF rs6265, CPLX2 rs1366116, rs3892909, NGF rs6330, rs4839435, NGFR rs734194, rs11466155, rs2072446, ANXAV rs11575945, BAX rs1057369 SNPs; (2) PTSD and CPLX2 rs1366116, BCL2 rs956572 SNPs; (3) IS and NTNG1 rs628117, CPLX2 rs1366116, ANXAV rs11575945 SNPs. The obtained results indicated the involvement of genetically determined alterations in synaptic plasticity and apoptosis in pathomechanisms of SCZ, PTSD and IS. The minor T allele of the CPLX2 gene rs1366116 polymorphism represents risk factor for all studied diseased conditions indicating important functional significance of this genetic variation in maintenance of synaptic plasticity. Another important conclusion of these studies is that minor alleles of some polymorphic variants of genes, encoding synaptic plasticity and apoptosis regulatory proteins, may play a protective role relative to SCZ decreasing the risk for development of this disorder. In summary, our studies emphasize the important contribution of changes in synaptic plasticity and apoptosis regulation to pathomechanisms of SCZ, PTSD, and IS as well as significant input of genetic factors to these changes.

show abstract

Nerve growth factor serum concentrations rise after successful cognitive–behavioural therapy of generalized anxiety disorder

Cited by 32 publications

References 18 publications

Neurotrophic gene polymorphisms and response to psychological therapy

Neurotrophic gene polymorphisms and response to psychological therapy

Mental disorders, functional impairment, and nerve growth factor

Genetic Variations Associated with Brain Disorders: Focus on Synaptic Plasticity and Apoptosis Regulatory Genes in Schizophrenia, Posttraumatic Stress Disorder and Ischemic Stroke

Contact Info

Product

Resources

About